Recruiting

Tracking HIV risk and infection in vulnerable young adults

Plain-English translation of NCT05147519 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

What is this trial?

This is an observational study that tracks people at higher risk of HIV infection over time. Researchers will test participants regularly for HIV and other sexually transmitted infections to better understand how and when infection occurs. The study has two phases: an initial monitoring phase for everyone, and a closer follow-up phase for people who receive a new HIV diagnosis.

Researchers need better data on how HIV spreads among people at higher risk so they can develop better prevention and treatment strategies. By tracking this population carefully, scientists hope to improve early detection and care.

Do you qualify?

You likely qualify if…

you are between 14 and 55 years old
you have tested negative for HIV at the start of the study
you are considered at higher risk for HIV based on recent infections (like syphilis or gonorrhea), sexual behaviors, injection drug use, or other factors in the past 6 months
you are willing to be tested for HIV and other infections every 12 weeks
you speak English or a local language approved by the study team and can understand the consent process

You likely don't qualify if…

you are pregnant or planning to become pregnant during the study
you have active alcohol or drug dependence that would make it hard to follow study visits
you have a serious medical, mental health, or social condition that would interfere with study participation
you have previously participated in an HIV vaccine trial (unless you received a placebo)
you have a positive HIV test at screening

What participation looks like

If you join Step 1, you will visit the study site every 12 weeks for HIV and infection testing over the duration of the study. If you receive a new HIV diagnosis during Step 1, you will move to Step 2, where you'll have more frequent visits—every 4 weeks for the first 12 weeks, then every 12 weeks for a total of 48 weeks—to monitor your viral load and overall health. All visits involve blood or other test samples and discussions about your health and behaviors.

AI-generated summary from trial data · Jun 9, 2026 · Not medical advice

Trial locations(4 sites)

Kenya

Kenya Medical Research Institute/ USAMRD-A/Kenya (Kericho), Kericho, Kericho County

Nigeria

Clinical Research Centre, Walter Reed Army Institute of Research -Africa/Nigeria (WRAIR-A/Nigeria), Abuja

Philippines

Institute of Clinical Epidemiology, National Institutes of Health, University of the Philippines Manila, Manila

Uganda

Makerere University Walter Reed Program, Makerere, Kampala